Formulation Plant

Baddi Plant

Unichem’s Baddi Plant is situated in Himachal Pradesh at a distance of 45 Km from the business hub of Chandigarh.

The total plot area of the manufacturing site is 1,32,000 sq.m and is the biggest formulation unit at Baddi, with a total build-up area of 37,716 sq.m.

Unichem Baddi Plant focuses on manufacturing different formulations of the Beta Lactam range of Antibiotics, General Products.

baddi-plant-latest

REGULATORY APPROVALS

The Baddi plant is approved by:

  • Medicines & Healthcare Products Regulatory Agency (MHRA) – U.K.
  • ANVISA – Brazil
  • Medicines Control Council (MCC) – South Africa
  • PICS – Malaysia
The manufacturing site at Baddi has three manufacturing units:
UNIT 1

Installed Capacity

Dosage Form M/Yr./Shift
Tablets 48
Capsules 240
Dry Syrup 6
Vial 5

Specialization

  • Tablets
  • Capsules
  • Dry Syrup
  • Dry Powder Injection

Markets

Slovenia, Tanzania, Oman, Ethiopia, Zimbabwe, Brazil, Uganda, Philippines, UK, Ghana, Malaysia, Nigeria, Kenya, South Africa, Ukraine, Malawi, UAE

Accreditations

  • JAZMP – Slovenia
  • TFDA – Tanzania
  • WHO GMP Inspection – India
  • MOH – Oman
  • FMHAC – Ethiopia
  • MCA – Zimbabwe
  • ANVISA – Brazil
  • NDA – Uganda
  • FDA – Philippines
  • MHRA Inspection – UK
  • FDB – Ghana
  • NPRA Malaysia – Sterile
  • NAFDAC Inspection – Nigeria
  • PPB Inspection – Kenya
  • NPRA – Malaysia (OSD)
  • Ministry of Health – Cambodia
  • MCC – South Africa
  • MOH – Ukraine
  • PMPB – Malawi
  • Ministry of Health – UAE
UNIT 2

Installed Capacity

Dosage Form M/Yr./Shift
Tablets 900
Capsules 450
Unienzyme Tablets 360

Specialization

  • Tablets
  • Capsules

Markets

Tanzania, Oman, Ethiopia, Brazil, Uganda, Philippines, Zimbabwe, Cambodia, Malaysia, Kenya, Nigeria, Ghana, Ivory Coast, Ukraine, Malawi, Sudan

Accreditations

  • TFDA – Tanzania
  • WHO GMP Inspection – India
  • MOH – Oman
  • FMHAC – Ethiopia
  • ANVISA – Brazil
  • NDA – Uganda
  • FDA – Philippines
  • MCAZ – Zimbabwe
  • Ministry of Health – Cambodia
  • NPRA – Malaysia (OSD)
  • PPB Inspection – Kenya
  • NAFDAC Inspection – Nigeria
  • FDA – Ghana
  • DPM – Ivory Coast
  • MOH – Ukraine
  • PMPB – Malawi
  • Federal Ministry of Health – Sudan
UNIT 3

Installed Capacity

Dosage Form M/Yr./Shift
Tablets 450

Specialization

  • Tablets

Markets

UK

Accreditations

  • MHRA
  •  WHO GMP
baddi-2nd-img

PLANT LOCATION

BADDI
Bhatauli Kalan,
District Solan, Baddi – 173 205
Himachal Pradesh.

Ghaziabad Plant

Situated about 20 km from New Delhi, Unichem’s Ghaziabad Plant has efficient infrastructure for manufacturing pharmaceutical products.

The Ghaziabad Plant was established in 1969 as the first multi-product Pharmaceutical plant. Over the years, Unichem has invested tremendous efforts to constantly improve quality standards and consistency.

In 2003, the manufacturing facility was completely upgraded to meet International standards for the manufacture of Pharmaceutical formulations.

ghaziabad-plant-latest

REGULATORY APPROVALS

The Ghaziabad plant is approved by:

  • Food and Drug Administration (US FDA)
  • Medicines & Healthcare Products Regulatory Agencies (MHRA), UK
  • ANVISA – Brazil
  • MOH – Russia
  • TFDA – Tanzania
  • Other regulatory authorities

Installed Capacity

Dosage Form M/Yr./Shift
Tablets 2000

Specialization

  • Tablets

Markets

USA, Europe, Brazil, Canada, South Africa, Russia, Belarus, Ukraine, Georgia, Kenya, Zambia, Oman, Malaysia, Uzbekistan

Accreditations

  • FDA – US
  • PPB – Kenya
  • MCC – South Africa
  • WHO GMP – Nigeria
  • MHRA – Uganda
  • Health – Canada
  • MCAZ – Zimbabwe
  • TFDA – Tanzania
  • ANVISA – Brazil
  • FDA – Ghana

Goa Plant

Unichem’s Goa plant is located at Pilerne, which is about 12 Km from the capital city Panjim. Built in 1997, it caters to the whole of Unichem’s export market.

The Goa plant is consistently meeting the Current Good Manufacturing Practices (cGMP) guidelines, WHO and other statutory requirements including zero water discharge criteria. This plant has been rigorously inspected, inter alia, by USFDA and MHRA on a regular basis as it caters to the majority of the European and American markets.

goa-latest

REGULATORY APPROVALS

The Goa plant is approved by:

  • Food and Drug Administration (US FDA)
  • Medicines Control Council (MCC) – South Africa
  • Medicines & Healthcare Products Regulatory Agency (MHRA) – U.K.
  • Therapeutic Goods Administration (TGA) – Australia
  • ANVISA – Brazil

Installed Capacity

Dosage Form M/Yr./Shift
Tablets 7000
Capsules 200

Specialization

  • Tablets
  • Capsules

Markets

USA, South Africa, UK, Australia, Brazil

Accreditations

  • FDA – US
  • MCC – South Africa
  • MHRA – U.K.
  • TGA – Australia
  • ANVISA – Brazil